The latest health news highlights Gerresheimer's rejection of a takeover bid from Silgan, researchers' progress with CRISPR for Down syndrome, Eli Lilly's obesity pill traction, Trump's push on ...

The company's strong cash position gives investors confidence in the gene-editing stock.

However, there is one key reason the stock could still deliver outstanding returns over the long run: Its pipeline could help ...

CRISPR biosensors are transforming healthcare by detecting biomarkers at attomolar sensitivity, enabling real-time health monitoring through wearable patches and implantable sensors. They continuously ...

Key market opportunities include advancements in research, medicine, diagnostics, and biotechnology through CRISPR. There is potential for innovative solutions and ethical exploration in gene editing, ...

Buying biotech stocks is a great way to add growth to your portfolio. This particular player won approval for its first product a couple of years ago, proving the strength of its game-changing ...

Candy maker Mars said Wednesday it has partnered with biotech company Pairwise to speed up the development of more resilient cocoa using CRISPR-based gene editing technology. CRISPR technology is a ...

Cathie Wood aims to identify innovators and invest in them early in their stories. Wood has been regularly adding to her position in this stock, and it’s one of her top holdings. 10 stocks we like ...

CRISPR Therapeutics is targeting multiple difficult-to-treat diseases with several candidates. The company's shares could soar if it delivers consistent clinical and regulatory progress. However, the ...

The issuer is solely responsible for the content of this announcement. BRAIN Biotech has been granted a key patent for its CRISPR-BMC genome-editing technology Newly patented CRISPR nuclease exhibits ...

Cathie Wood and Wall Street don't always agree. The chief executive officer of Ark Invest has been more bullish on Tesla, for example, than the general analyst community and has taken advantage of ...